Allergy & Asthma Proceedings
OceanSide Publications · 95 Pitman Street · Providence, Rhode Island 02906
Phone: (401) 331-2510 · Fax: (401) 331-0223
E-mail:
Allergy & Asthma Proceedings
Am J Rhinol & Allergy
Allergy & Rhinology
View Online Journal Content
Free Trial
Table of Content Alerts
Subscription Information
Editorial Board
Manuscript Submission
FastTrack Service
Open Access
Expedited Manuscript Service
Advertising Opportunities (PDF)
Reprints, Rights, Permissions
AAP History
RSLAAIS
Related Links
Contact Us
Frequently Asked Questions
OceanSide Publications Home
Join Our Mailing List
Enter your email address:

Instructions to Authors






Editor-in-Chief
Joseph A. Bellanti, M.D.

Allergy and Asthma Proceedings utilizes an online system of manuscript submission, editing and review. This system allows authors to submit their work online and check on the status of the review process. To access the electronic system, visit http://aap.msubmit.net. This technology requires all manuscript files be uploaded separately as follows:

1.) cover letter
 
2.) manuscript (including title page, abstract, text, references and figure legends only) excluding table and figure files
3.) tables (can be consolidated into one "tables" file or uploaded separately)
 
4.) figures (preferably uploaded separately)

Copyright release forms and conflict of interest forms must be sent via mail or fax. Forms may be downloaded: Publishing Forms (pdf file). If figures are scanned, please also forward the original (glossy) figures to the editorial offices. These will produce a higher quality output in the printing process. Electronic submission is a four step process that is described step-by-step on the http://aap.msubmit.net site. Allergy and Asthma Proceedings will no longer accommodate the submission of paper manuscripts unless prior permission is granted via the editorial office. Please contact the editorial offices with any questions regarding the submission process.

MANUSCRIPT PREPARATION GUIDELINES:
Please note: Failure to follow these format instructions may result in the manuscript being returned to the author(s) for revision prior to review

SELECTING A MANUSCRIPT TYPE: when uploading your completed manuscript, you will be required to designate a manuscript type.

Please note: Failure to follow these format instructions may result in the manuscript being returned to the author(s) for revision prior to review SELECTING A MANUSCRIPT TYPE: when uploading your completed manuscript, you will be required to designate a manuscript type.

The following are guidelines for choosing:

  • Review: Manuscript that provides a review of previously published literature. Components indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures)

  • Original manuscript: Provides the results of original laboratory and/or clinical research. Components indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures)

  • Letters to the Editor: Letters to the editor will be reviewed by the Editor(s) and peer-reviewed. Letters to the editor are limited to 500 words and 5 references. As letters to the editor are indexed and cited like original articles, key words are also required.

  • Case Reports: With the exception of the POPS Case Reports (exclusively for FITs), Allergy and Asthma Proceedings does not encourage the submission of case reports. Only those submitted that are truly unique and have an exceptional teaching value will be considered for publication.

  • Solicited Meeting paper: If the solicited manuscript was written based upon a presentation at a scientific meeting of either the Eastern Allergy Conference or the Southwest Allergy Forum, please select this manuscript type. Components indicated by a checkmark below should appear in the order they are presented here (i.e. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures). The corresponding scientific meeting should be included on the title page in the format of the name of the meeting, city, state (or country), date of meeting. i.e. "Presented at the Eastern Allergy Conference, Naples, Florida, May 15, 2012"

  • Solicited Symposium: If the manuscript was solicited to precede, accompany or follow a pre, mid or post-conference symposium presentation at a scientific meeting of either the Eastern Allergy Conference (EAC) or the Combined EAC/Southwest Allergy Forum, please select this manuscript type. The corresponding scientific meeting should be included on the title page in the format of the name of the meeting, city, state (or country), date of meeting. i.e. "Presented at the pre-conference symposium of the Eastern Allergy Conference, Naples, Florida, May 15, 2012" Symposium manuscripts are supported by unrestricted educational grants which must be disclosed on the title page of the manuscript. i.e. "Supported by an unrestricted educational grant from Z Pharmaceuticals" Components indicated by a checkmark below should appear in the order they are presented here (ie. title page, abstract, manuscript text, acknowledgment, references, figure legends, tables, figures)

  • POPS Case Reports: Submissions are limited to A/I FITs only. APPENDIX A FOR ADDITIONAL INSTRUCTIONS

  • Clinical Pearls and Pitfalls: The objective of the Clinical Pearls section of the Allergy and Asthma Proceedings is to provide the reader with a brief and concise review of a given topic. Emphasis should focus on salient clinical features and topics of interest for both the practicing physician as well as the fellow-in-training. Manuscripts should consist of one question followed by a brief and concise review following a strictly structured format. SEE ATTACHED APPENDIX B FOR FORMAT GUIDELINES AND ADDITIONAL INSTRUCTIONS

Title page
Include full relevant and concise (no more than 15 words) title in sentence format (only capitalize proper nouns). Never include abbreviations in the title.
First name, middle initial, last name of each author with highest academic degrees included (do not include fellowships)
Name of Departments and Institutions to which work should be attributed; (see Conflict of Interest below)
Disclaimers (if any); and Acknowledgment of Financial Support/Funding.(see Conflict of Interest)
In studies involving human subjects, a statement describing approval by the Institutional Review Board is required.
Key Words (10 key words are mandatory) Selecting appropriate key words is essential to your research being discovered by others.
Include date of presentation at scientific meeting (if any)
Include corresponding author's telephone number, FAX number and e-mail address

Abstract: All manuscript types with the exception of the Letters to the Editors must include a structured abstract, no longer than 250 words, to precede article. Only include acronyms or abbreviations if the phrase appears more than three times in the abstract. Divided abstract into the following sections:
Background - Describe the problem that prompted the study
Objective - Describe the purpose of the study
Methods - Describe how the study was conducted
Results - Describe the most important findings
Conclusion - Describe the most important conclusion drawn from the study

Text: unspecified length for all manuscript types excluding POPS Case Reports and Clinical Pearls. [See Appendix A for POPS Case Report text format and Appendix B for Clinical Pearls text format.] Manuscript should be typed double-spaced in a standard font such as Times New Roman, Arial, Courier, or Helvetica, in size 12. Manuscript text pages should be numbered. Text should be written in clear and concise English. Authors whose primary language is not English should obtain assistance with writing to avoid grammatical problems. Several independent services for STM authors are available online and include:

 US based: www.biomeditor.com
www.biosciencewriters.com
www.bostonbioedit.com
www.academicword.com
www.writescienceright.com
www.journalexperts.com
UK based: www.bioedit.co.uk
www.internationalscienceediting.com
Asia based: www.ahediting.com -- click here to view company profile (PDF)
Asia Pacific based - India: www.asiascienceediting.com
Japan: www.edanzediting.nl
Australia: www.oleng.com.au
Philippine: www.prof-editing.com

Please note: These few sites are only listed as a convenience and are not an endorsement of their products. They are in no way affiliated with the journal and use of their services will not guarantee acceptance of a manuscript.

Acknowledgment: General acknowledgments for consultations, statistical analysis and such should be listed at the end of the text before the References. Include full names of individuals. Any and all acknowledgments of funding must be included on the title page.

References: References in the text should be superscript numbers in order of appearance. Manuscripts in preparation, personal communications, websites, or other unpublished information should not be cited in the reference list but may be mentioned in the text in parentheses. References with more than three authors should be presented as the first three authors followed by et al. Please follow format below, e.g.:

1.  Meltzer EO. Intranasal anticholinergic therapy of rhinorrhea. J Allergy Clin Immunol 1992; 90:1055-1064.
2.  Benson S, Olnes S, Phil A, et al. On the mechanism of protein synthesis inhibition by abrin and ricin. Eur J Biochem 1975; 59:573-588.
3.   Swift DL, and Proctor DF. Access of air to the respiratory tract. In Respiratory Defense Mechanisms. Brain JD, Proctor DF, and Reid LM (Eds). New York: Marcel Dekker, 1977; 21-40.

Tables: Tables may be placed within the manuscript or uploaded as separate files (in .doc or .wpd format). If table is included in manuscript file, place after the References section, one table per page. Any abbreviations included in the table should be defined at the bottom of the table. If the table is being republished with permission, proof of permission must be faxed to the editorial office.

Figure legends: Figure legends should be typewritten, double-spaced and listed (numbered) on a separate page after the tables. They should not appear on the figures. Include figure titles at the beginning of the legend.

Figures, and illustrations: Illustrations included in manuscripts must be submitted in electronic format along with the rest of the manuscript. Each figure should be submitted as a separate electronic file - not imbedded in the manuscript text file. See Cadmus guidelines for submitting digital art at http://cpc.cadmus.com/da/guidelines.asp. Figure file preference is .tif, .jpeg, .eps. Proof of permission must be faxed to the editorial office for any figures being republished with permission. Proof of informed consent (signed releases) must be faxed to the editorial office for any and all photographs of identifiable persons.
[See Appendix A for additional information on Figures for POPS Case Report submissions.]
A note about color figures: If your manuscript is accepted for publication and it includes color figures, you will have an option of printing your figures in color or black and white. Due to the high cost of color, please be aware that if you choose to print in color, the cost to you will be $800. There is no cost to print the figures in black and white. Figures submitted in color but printed in black and white will appear at no cost, in color on the online version of the journal.

Copyright release form: MANUSCRIPTS WILL NOT BE REVIEWED UNLESS ACCOMPANIED BY A COPYRIGHT RELEASE FORM SIGNED BY EACH AND EVERY AUTHOR which states "The undersigned author(s) transfer all copyright ownership, including electronic, of the manuscript (title of article) to OceanSide Publications, Inc in the event the work is published. The undersigned warrant(s) that the article is original, does not infringe upon any copyright or other proprietary right of any third party, is not under consideration by another journal, and has not been previously published. The author(s) confirm that they have reviewed and approved the final version of the manuscript." Items are accepted for publication on the understanding that they are contributed solely to Allergy and Asthma Proceedings and have not been or will not be published elsewhere in any format except in abstract form. Blank Copyright Release forms may be downloaded: Publishing Forms (pdf file).

Conflict of Interest form: Allergy and Asthma Proceedings requires all authors listed on the title page of the manuscript to make the following disclosures: On the title page of the manuscript, authors must acknowledge:
a. all funding sources that supported their work and
b. all institutional or corporate affiliations of each author
Also, All authors must submit a separate form (one for each author) stating specifically whether any of the following commercial associations that might pose a conflict of interest exists: consultant arrangements, stock or other equity ownership, patent licensing arrangements, or payments for conducting or publicizing the study. Contact Allergy and Asthma Proceedings for blank Conflict of Interest forms or download them Publishing Forms (pdf file). Disclosures will be held in strict confidence during the review process and will not influence any editorial decisions. However, if the paper is accepted for publication, the Editor will determine how any conflict of interest should be disclosed.

Appendix A

Patient-Oriented Problem Solving (POPS) Case Report Author Instructions
(limited to Allergy-Immunology Fellows-in-Training)

The purpose of the POPS series is to provide an innovative and practical learning experience for the allergist-immunologist using a format of clinical presentation, physical findings, appropriate laboratory studies and differential diagnosis. The case development should be prepared in a logical sequence, withholding the announcement of the diagnosis until the end of the presentation.

Only six case reports will be accepted for publication per year. Case reports will be evaluated on a first come, first serve basis. Case reports should be submitted online at http://aap.msubmit.net. Submissions are limited to A/I FITs only.

Author Instructions

1.  Abstract: no longer than 250 words. Please prepare the title and abstract, in a manner which should not give away the diagnosis of the case, but rather review the differential diagnosis. See the following two examples of abstracts from previously published POPS cases, referenced below:

Dhanani K, Shanmugam G, Khan DA. A 6-year-old boy with fever and eosinophilia. Allergy Asthma Proc. 2009 Nov-Dec;30(6):655-9. PubMed PMID: 20031012.

Lee RU, Woessner KM, Mathison DA. Surfer's asthma. Allergy Asthma Proc. 2009 Mar-Apr;30(2):202-5. PubMed PMID: 19463209.
2. Manuscript length: not to exceed 1,500 words excluding abstract, tables, figures and references and entire document not to exceed 10 double-spaced typewritten pages.
3.   Tables: Not to exceed two tables with no more than 30 words per table legend
4. Figures: Not to exceed two figures with no more than 30 words per figure legend
5. Reference: Follow style provided on General Instructions to Authors. Please attempt to relate the case report to recently published work in the Proceedings
6. Conflict of interest: see General Instructions for Authors
7. Copyright release: see General Instructions for Authors

Format:
Case report: Chronological review of case clinical presentation: history and physical exam, diagnostic studies, treatment and clinical course.

The following headers (in bold text) should be incorporated into the manuscript:

CHIEF COMPLAINT
HISTORY OF PRESENT ILLNESS
PHYSICAL EXAMINATION
LABORATORY & OTHER DIAGNOSTIC FINDINGS
(X ray, MRI, CT scans, biopsy, etc.)
CLINICAL COURSE
QUESTIONS
1. What is the differential diagnosis?
2. What additional laboratory data or investigations would be helpful in arriving at a diagnosis in this patient?

DISCUSSION:

  • Detailed discussion of the case being presented should include the following content:
    • Clinical and laboratory features of the disorder (including disease course if applicable)
    • Diagnosis and differential diagnosis
    • Therapeutic options

FINAL DIAGNOSIS: (The diagnosis should not be revealed to the reader until the case develops to this stage.)
SUMMMARY (or CONCLUSIONS)

Appendix B

Clinical Pearls and Pitfalls

Additional Author instructions

1. The objective of the Clinical Pearls section of the Allergy and Asthma Proceedings is to provide the reader with a brief and concise review of a given topic.  Emphasis should focus on salient clinical features and topics of interest for both the practicing physician as well as the fellow-in-training.
2. Each Clinical Pearls section should consist of one question followed by a brief and concise review.  The author should pose the question then follow with a brief review, bulleted Clinical Peals, and bulleted Clinical Pitfalls.
3.  The overall length should not exceed 1500 words, excluding references.  There should not be more than 10 references.
4. This communication should follow the format listed below:

      Posed question

  Possible answers (choices A through E)

  Introduction

  Clinical Characteristics and Pathophysiology

  Diagnosis

  Management

  Correct answer to posed question

  Pearls in bulleted format
  • Pearl 1
  • Pearl 2
  Pitfalls in bulleted format
  • Pitfall 1
  • Pitfall 2
5. References – see General Instructions to Authors Conflict of interest
6. Conflict of interest - see General Instructions to Authors
7. Copyright release - see General Instructions to Authors

Click here for a printable version of Instructions to Authors (pdf file).


Appendix c

Allergy and Asthma Proceedings Abstract Submission Overview

Click here for a printable version of this Abstract Submission Overview and Abstract Submission Form (pdf file).

AAP only accepts abstracts, which are submitted in associated with RSL Allergy Society CME meetings. As a part of this process.

  • All abstracts must be submitted through the submission page of the journal's website:
    http://aap.msubmit.net
  • Abstract corresponding authors will receive E-mail notification of the abstract receipt and status.
  • The abstract review committee (program committee) will review all abstracts via the submission site.

 
Abstract Submission Instructions
 
1.) The abstract must adequately describe the objectives, methods, results and conclusions so the the Abstract Committee may evaluate the quality of the work and proposed presentation.
 
2.) The abstract title should fully reflect the content of the abstract body.
 
3.) A structured abstract format is preferable; that is, all abstracts should contain these sections: Introduction (background information and purpose of the project/study), Methods (study design, techniques), Results (summary of data), and Conclusions.
 
4.) The authors must accept sole responsibility for the statements in their submitted abstract.
 
5.) Illustrations and talbes are not permitted.
 
6.) Supplementary data are not accepted under any circumstances.
 
7.) Abbreviations must be used in the abstract if such abbreviations are defined at their first mention.
 
8.) The abstract length is limited to 250 words.
 
9.) Abstracts are submitted for poster presentation. Oral presentations are not available.
 
10.) Authors are encouraged, but not required to submit for peer review and publication. Any subsequent full length manuscripts which derive from the submitted abstract.
 
11.) A maximum of 5 authors must be specified in the abstract submission process; however, any subsequent full length manuscripts may have more than 5 authors. Corresponding authors for accepted abstracts may request the addition of additional authors to their abstracts by submitting a request to the Managing Editor, Susan Colucci, at susancolucci@oceansidepubl.com.
 
12.) Each abstract submission must specify a corresponding author, to whom all correspondence about the abstract will be directed.
 
13.) All abstracts will be assigned an identification number which should be used for all communications about an abstract.
 
14.) The presenter of each accepted abstract must register for the scientific meeting in the standard fashion see www.easternallergyconference.org.
 
15.) Where ever possible, noncommercial (generic) names must be used in all abstracts and posters. The editorial staff may request a revised submission of the abstract to enforce compliance with this ACCME requirement.
 
16.) All authors must agree to disclose all non-FDA appproved use of FDA approved drugs during the abstract submission process as well as in the actual presentation (oral or poster).

Fees:

Submission for content review (only): $50. This fee applies to all submitted abstracts, regardless of whether the author is requesting publication.


Submission for Publication: $300 for supported work; $0 for unsupported work (RSL Allergy Society members). Authors have the options for their abstracts to be published in an upcoming issue of the journal, Allergy & Asthma Proceedings. The fee for the publication of supported abstracts is faxed (401) 331-0223, or emailed (susancolucci@oceansidepubl.com) to the Editorial office at the time of submission. Of note, because of possible copyright infringements, abstracts which have been submitted for publication elsewhere will not be published inAllergy & Asthma Proceedings.

Click here for a printable version of this Abstract Submission Overview and Abstract Submission Form (pdf file).



   OceanSide Publications
   95 Pitman Street · Providence, Rhode Island 02906

   Phone: (401) 331-2510 · E-mail:
oceanside@oceansidepubl.com
  Website: www.allergyandasthmaproceedings.com
Copyright © 2012.  
All rights reserved.